MedTrace Logo

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1287

Last updated 2025-11-06

Study results available
· View outcomes & findings →

Summary

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

Conditions

  • Atrial Fibrillation (AF)
  • Stroke

Interventions

BIOLOGICAL

Abelacimab

Abelacimab provided as liquid in vial (150 mg/mL)

DRUG

Rivaroxaban

Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2024-02-15
Completion
2028-12-29
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Czechia
  • Hungary
  • Poland
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04755283 on ClinicalTrials.gov